| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $998,207 | 1 | 100 |
Sells | $0 | 0 | 0 |
| ORBIMED ADVISORS LLC | 10 percent owner | 1 | $998,207 | 0 | $0 | $998,207 |
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through …
Over the last 12 months, insiders at Traws Pharma, Inc. have bought $998,207 and sold $0 worth of Traws Pharma, Inc. stock.
On average, over the past 5 years, insiders at Traws Pharma, Inc. have bought $998,207 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC (10 percent owner) — $998,207.
The last purchase of 597,729 shares for transaction amount of $998,207 was made by ORBIMED ADVISORS LLC (10 percent owner) on 2026‑04‑16.
| 2026-04-16 | ORBIMED ADVISORS LLC | 10 percent owner | 597,729 10.3238% | $1.67 | $998,207 | -51.07% |
| Increased Positions | 14 | +73.68% | 2M | +175.05% |
| Decreased Positions | 7 | -36.84% | 169,691 | -13.01% |
| New Positions | 8 | New | 1M | New |
| Sold Out Positions | 5 | Sold Out | 163,390 | Sold Out |
| Total Postitions | 26 | +36.84% | 3M | +162.04% |